whether a DOUBLE dose of clopidogrel (Plavix) prevents more cardiovascular events in stent patients

February 2011

Experts are debating whether a DOUBLE dose of clopidogrel (Plavix) prevents more cardiovascular events in stent patients.

Up to 25% of patients don't respond well to clopidogrel's antiplatelet effects...and are at higher risk for a cardiac event.

So some prescribers order platelet function tests to identify patients who have high platelet activity despite clopidogrel therapy.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote